Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.

Frontiers in immunology - 1 Jan 2020

Punta Marco, Jennings Victoria A, Melcher Alan A, Lise Stefano

Abstract excerpt

Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation properties of mutations that are known to drive resistance to cancer targeted-therapies. We survey a large dataset of mutations that confer resistance to different drugs and occur in numerous genes and tumor types. We show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines
Share to Computer Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 33133066
DOI: 10.3389/fimmu.2020.524968
PMCID: PMC7578429

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.PMID 33133066Read ↗

The immunogenic potential of recurrent cancer drug resistance mutations: an <i>in silico</i> studySemantic proximity Read ↗

Identification and Ranking of Recurrent Neo-Epitopes in CancerSemantic proximity Read ↗

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors.Semantic proximity Read ↗

Identification and ranking of recurrent neo-epitopes in cancer.Semantic proximity Read ↗

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumorsSemantic proximity Read ↗

A census of predicted mutational epitopes suitable for immunologic cancer control.Semantic proximity Read ↗

Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy TargetsSemantic proximity Read ↗

Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapySemantic proximity Read ↗

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.Semantic proximity Read ↗

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Semantic proximity Read ↗

Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.Semantic proximity Read ↗

Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.